Figures & data
Table 1. Cancer location and time to primary malignancy.
Table 2. Primary colorectal examination.
Table 3. Subjects with elevated cancer-associated biomarkers.
Figure 1. Cumulative incidence of malignancy according to plasma/serum levels of A: CEA (p = .0008), B: TIMP-1 (p = .02), C: CA19-9 (p = .002) and D: YKL-40 (p = .002). The solid blue lines represent normal levels of the cancer-associated biomarkers with 95% CI. The dotted red lines represent elevated levels of the cancer-associated biomarkers with 95% CI.
![Figure 1. Cumulative incidence of malignancy according to plasma/serum levels of A: CEA (p = .0008), B: TIMP-1 (p = .02), C: CA19-9 (p = .002) and D: YKL-40 (p = .002). The solid blue lines represent normal levels of the cancer-associated biomarkers with 95% CI. The dotted red lines represent elevated levels of the cancer-associated biomarkers with 95% CI.](/cms/asset/9bec41ad-75d2-485f-b0dc-2b8bf207ab70/ionc_a_1540885_f0001_c.jpg)
Figure 2. Cumulative incidence of malignancy according to the multivariate analysis including the three defined groups (p = .0009). The solid blue line with 95% CI, represents group 0 with none of the four biomarkers elevated. The dotted red line with 95% CI, represents group 1, with one of the four biomarkers elevated. The dotted green line with 95% CI, represents group 2, with two or more of the four biomarkers elevated.
![Figure 2. Cumulative incidence of malignancy according to the multivariate analysis including the three defined groups (p = .0009). The solid blue line with 95% CI, represents group 0 with none of the four biomarkers elevated. The dotted red line with 95% CI, represents group 1, with one of the four biomarkers elevated. The dotted green line with 95% CI, represents group 2, with two or more of the four biomarkers elevated.](/cms/asset/0f33a1e3-eaf7-4ca3-98c9-ab26baa342f5/ionc_a_1540885_f0002_c.jpg)